

RESEARCH

Open Access



# Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF- $\kappa$ B signaling pathways

Khalid Otmani<sup>1\*</sup>, Redouane Rouas<sup>1</sup>, Laurence Lagneaux<sup>2</sup>, Mohammad Krayem<sup>3</sup>, Hugues Duvillier<sup>4</sup>, Mimoune Berehab<sup>1</sup> and Philippe Lewalle<sup>1\*</sup>

## Abstract

**Background** microRNAs (miRNAs) are known as potent gene expression regulators, and several studies have revealed the prognostic value of miRNAs in acute myeloid leukemia (AML) patient survival. Recently, strong evidence has indicated that miRNAs can be transported by exosomes (EXOs) from cancer cells to recipient immune microenvironment (IME) cells.

**Results** We found that AML blast-released EXOs enhance CD3 T-cell apoptosis in both CD4 and CD8 T cells. We hypothesized that miRNAs present in EXOs are key players in mediating the changes observed in AML T-cell survival. We found that miR-24-3p, a commonly overexpressed miRNA in AML, was present in released EXOs, suggesting that EXO-miR-24-3p was linked to the increased miR-24-3p levels detected in isolated AML T cells. These results were corroborated by ex vivo-generated miR-24-3p-enriched EXOs, which showed that miR-24-3p-EXOs increased apoptosis and miR-24-3p levels in T cells. We also demonstrated that overexpression of miR-24-3p increased T-cell apoptosis and affected T-cell proliferation by directly targeting DENN/MADD expression and indirectly altering the NF- $\kappa$ B, p-JAK/STAT, and p-ERK signaling pathways but promoting regulatory T-cell (Treg) development.

**Conclusions** These results highlight a mechanism through which AML blasts indirectly impede T-cell function via transferred exosomal miR-24-3p. In conclusion, by characterizing the signaling network regulated by individual miRNAs in the leukemic IME, we aimed to discover new nonleukemic immune targets to rescue the potent antitumor function of T cells against AML blasts.

**Keywords** AML, miR-24-3p, T cells, Immune response, Apoptosis

\*Correspondence:

Khalid Otmani  
otmani\_khalid001@hotmail.com  
Philippe Lewalle  
Philippe.lewalle@hubruxelles.be

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

The treatment of acute myeloid leukemia (AML) has long been based on the concept that leukemic blasts can be eliminated only by drugs acting directly against the blast itself [1]. According to this presupposition, anti-cell cycle drugs are considered central in AML treatment, and strategies to modulate the immune system were initially believed to be ineffective [2–4]. However, several studies have shown the capacity of cancer to induce apoptosis in immune cells, and impaired antitumor activities of T cells are a major means of cancer cell survival. Currently, T-cell apoptosis induction by cancer cells is a well-characterized specific tumor resistance mechanism [4]. In AML, blasts were shown to directly alter CD8+ T-cell viability, expansion, cosignaling and senescence marker expression [5].

In recent years, emerging evidence has demonstrated that communication between various types of immune microenvironment (IME) cells and cancer cells occurs via exosomes (EXOs) containing a wide range of miRNAs and several other components, such as proteins and mRNAs [6]. microRNAs (miRNAs) are a class of short transcripts that regulate gene expression post-transcriptionally [7, 8]. miRNAs function as crucial regulators of the immune response in both physiological and pathological conditions [9]. Interestingly, miRNA functions can be harnessed by cancer cells to transform the IME [6, 10–14]. In leukemia, EXO-miRNAs were reported to contribute to the transformation of the IME into a tumor-favorable niche [14].

Here, we studied exosomal miR-24-3p and its effect on T cells in AML. miR-24-3p was shown to be involved in regulating cell proliferation and apoptosis, and its expression was found to be dysregulated in several cancers, where it has often been described as a prognostic indicator [15–17]. In AML, miR-24-3p was reported to be highly overexpressed and considered oncogenic. High expression of this molecule was associated with poor prognosis and risk of relapse [18]. Although many biomarker studies have examined circulating miRNA levels in AML, the regulatory effects of AML EXO-miRNA on T-cell functions have not been elucidated. Here, we aim to investigate the mechanism of action of circulating miR-24-3p on AML patient T-lymphocytes. We aimed to help elucidate the EXO-miRNA regulatory mechanisms in AML and contribute to the development of innovative immunotherapy strategies to facilitate leukemia treatment.

## Materials and methods

### Purification of peripheral blood CD3 T cells

Samples were collected from patients newly diagnosed with AML prior to treatment with chemotherapy or

radiotherapy ( $n=16$ ) and healthy donors (HDs) ( $n=7$ ). Peripheral blood samples were collected on anticoagulant citrate dextrose formula-A (ACD-A) (1:10) from donors and AML patients after informed consent was obtained. Purification of CD3 T cells was performed using a Miltenyi kit for CD3 immunomagnetic isolation (# 130–050–101). CD4 (# 130–096–533). CD8 (# 130–045–201) were obtained.

### EXO isolation

EXOs were isolated as previously described [19], and supernatants collected from 5-day cell cultures were first centrifuged at  $500\times g$  for 10 min to remove any cell contamination and debris. Next, the upper supernatant was further centrifuged at  $12,000\times g$  for 20 min to remove any possible apoptotic bodies and large cell debris. The final centrifugation was performed at  $100,000\times g$  for one hour to enrich the EXOs, and the pellet was washed in PBS. Finally, the EXOs were diluted in excess PBS via ultracentrifugation ( $100,000\times g$ ) for 70 min. The number and morphology of EXOs were examined by the use of a NanoSight NS300 microscope.

### Treg cell isolation

Peripheral blood samples were collected in tubes with anticoagulant from HDs after informed consent was obtained. CD4+CD25+CD127<sup>low</sup> regulatory T cells were purified from human EDTA-anticoagulated whole blood using the MACSxpress Miltenyi kit for CD4+CD25+CD127 Treg isolation (# 130–109–557).

### RNA extraction and qRT-PCR

Total RNA from cells was extracted by using TRIzol reagent (Thermo Fisher Scientific, Merelbeke, Belgium) according to the manufacturer's guidelines, and the concentration was quantified by a NanoDrop spectrophotometer. miRNA quantification was performed by TaqMan miRNA assays (Applied Biosystems a Thermo Fisher Scientific, Merelbeke, Belgium). The data were analyzed with the comparative Ct method, and RNAU44 was used as an endogenous control for normalization to determine the relative miRNA expression in T cells. For quantification of exosomal miRNAs, *Caenorhabditis elegans* miR-39 (cel-miR-39; Thermo Fisher) was spiked into the samples at the onset of the RNA extraction. Quantitative miRNA expression data were acquired and analyzed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). The primers listed in a table are provided in the [supplementary data](#).

### Quantitative PCR (qPCR) for target gene

Total RNA from cells was extracted by using TRIzol reagent (Thermo Fisher Scientific) according to the

manufacturer's guidelines, and the concentration was quantified by a NanoDrop spectrophotometer. First-strand cDNA was synthesized by reverse transcription (Quanta Script Kit). Quantitative mRNA expression was measured via qPCR, and the endogenous gene GAPDH was used as an internal control.

#### Western blot analysis

Cell lysates were subjected to SDS-PAGE electrophoresis and transferred to the membrane. The membranes were blocked and incubated with different primary antibodies against JAK1, JAK3, STAT1, STAT3, NF- $\kappa$ B, IKK, ERK, differentially expressed normal versus neoplastic/MAPK-activating (DENN/MADD), TNFR1, Bcl2, XIAP, Caspase 9 and Caspase 3 diluted 1:1000 (Cell Signaling Technology). Following 1 h of incubation with secondary antibody (1:10000), proteins were detected via the electrogenerated chemoluminescence method (Amersham Biosciences, Saclay, France) according to the manufacturer's instructions. All the protein signals were visualized using a LAS-3000 image reader (FUJI).

#### Lentivirus production and transduction

Here, we used PMIRH000-PA-1 from System Bioscience as a lentiviral vector in which an mRNA processor was cloned downstream of a CMV promoter and contained copGFP as a reporter gene. The lentivirus vector was produced by GIGA Firme Liège, Belgium. CD3, CD4 and CD8 T cells were extracted from HDs and patients with AML and plated at a density of  $2.10^6$  cells/well in 6-well tissue culture plates in 500  $\mu$ l of RPMI 1640 with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 units/ml penicillin, and 50  $\mu$ g/ml streptomycin (Lonza) in the presence of 5  $\mu$ g/ml phytohemagglutinin (PHA-L; Sigma) and 20 units/ml IL-2. Forty-eight hours after activation of CD3 T cells, we exposed the cells to the lentiviral vector preparation at a multiplicity of infection of 10 in 500  $\mu$ l in the presence of 8  $\mu$ g/ml polybrene (Sigma). EGFP-positive cells were evaluated by flow cytometry at day 6 after transduction.

#### Apoptosis determination (flow cytometry)

Apoptotic cells were measured with an Annexin V-PE Apoptosis Detection Kit I (BD Pharmingen, Erembodegem, Belgium) according to the manufacturer's recommendations. The cells were pelleted by brief centrifugation (200 g, 5 min) and suspended in 100  $\mu$ l of  $1\times$  annexin buffer (BD Pharmingen). After the addition of 5  $\mu$ l of annexin V-FITC and 5  $\mu$ l propidium iodide (PI), after incubation, the cells were diluted with 400  $\mu$ l of annexin buffer and analyzed within one hour in a flow cytometer (FACS) machine (NAVIOS-Beckman Coulter,

Suarlée, Belgium), and the data generated were analyzed by KALUZA software (Beckman Coulter).

#### Luciferase assay

A human DENN/MADD 3' untranslated region (UTR) fragment containing a wild-type (WT) or a mutated (MT) miR-24-3p binding sequence was cloned downstream of the luciferase reporter gene. The WT and Mut DENN/MADD 3'UTR plasmids were obtained from GeneCopia (USA). The plasmids were independently transfected into K562 cells with or without miR-24-3p mimics or scramble miRNA by using the Lipofectamine<sup>TM</sup> 3000 kit (Invitrogen, CA, USA). Renilla luciferase plasmids were cotransfected for normalization. A pGL3-control vector was cotransfected as a positive control. A dual luciferase reporter gene assay kit (GeneCopia, USA) was used to detect luciferase activity. Each experiment was performed in triplicate, and the data represent the mean  $\pm$  SE from three independent experiments.

#### Establishment of primary T-cell and cell line cultures

The isolated CD3, CD4, and CD8 primary T-cell and human leukemia K562, HL60 and KG1 cell lines (purchased from Sigma) were propagated in culture media: RPMI 1640 with 10% heat-inactivated fetal calf serum (FBS; Thermo Fisher Scientific, Merelbeke, Belgium) and with L-glutamine, penicillin and streptomycin at standard concentrations [all from Gibco, Invitrogen, United Kingdom (UK)] in humidified air with 5% CO<sub>2</sub> at 37 °C. The cell culture media were renewed every 2–3 days. Once the cells were at or near confluence, they were subcultured. Melanoma primary cultures were regularly assessed for mycoplasma contamination via a MycoAlert<sup>®</sup> Mycoplasma Detection Kit (Lonza, Rockland, ME, USA).

#### Cell transfection with miRNA mimics

The overexpression or inhibition of miR-24-3p in T cells for further Western blot analysis was achieved with miR-24-3p mimics or miR-24-3p-inhibitor mimics, respectively, which were purchased from Invitrogen. miR-NC and anti-ctrl were used as controls for the miR-24-3p mimic. The transfection of T cells was performed with a Thermo Fisher kit (Catalog # 4464066).

#### Statistical analysis

All of the data were analyzed by GraphPad Prism 6. Pearson correlation analysis was used to determine the correlation between miR-24-3p expression and DENN/MADD expression. Either a one-way analysis of variance (ANOVA) or a two-tailed unpaired Student's T test was used to determine the significance of the data for all the


experiments. Significance was determined when  $p < 0.05$ . Further details can be found in each figure legend.

## Results

### AML EXOs impede T-cell viability

In this study, we investigated the effect of leukemic released EXOs (R-EXOs) on T-cell viability by fluorescence-activated cell sorting (FACS). Initially, T cells sorted from the peripheral blood of healthy control donors were coincubated with R-EXOs. The studied EXOs were isolated by ultracentrifugation from the blast culture supernatant of eight AML patients at diagnosis or from HD peripheral blood mononuclear cell (PBMC) cultures. EXOs were verified via NanoSight

microscopy as small vesicles exhibiting a typical round morphology with a diameter of approximately 150 nm. The size distribution of the EXOs was predominantly within the range of 50 to 150 nm (Fig. 1A). As high expression of CD81 and CD63 is known as a typical marker of EXOs, we confirmed their expression on all our EXOs by FACS, confirming that the isolated vesicles were EXOs (Fig. 1B). The expression of the myeloid blast marker CD33 confirmed that these EXOs were derived from leukemic blasts (Fig. 1B). To determine the induction of T-cell apoptosis following R-EXO coincubation, we performed FACS analysis and measured the percentage of apoptotic T cells. We found that the apoptosis of CD3 T cells, including




**Fig. 1** Impact of leukemic EXOs on CD3+ T-cell viability: **(A)**, a representative electron microscopic image of EXOs isolated by ultracentrifugation from AML blast 5-day culture supernatant and characterized by nanoparticle tracking analysis (NTA). The EXOs ranged in size from 50 to 150 nm, with a mean value of 100 nm. The concentration of EXOs reached 10 µg/ml. **B** Representative FACS histogram plots of an EXO sample stained with anti-CD63 and anti-CD81, which are typical markers of EXOs, confirming that the isolated vesicles are EXOs, and with anti-CD33, a myeloid blast marker, confirming that the EXOs are derived from leukemic blasts. **C, D,** and **E** Purified CD3, CD4 and CD8 T cells from HDs were cultured with 8 R-EXO samples isolated from AML blast patients or EXOs from HD PBMCs in the presence of IL-2 for 5 days. The purity of the isolated T cells was above 98%, as assessed by flow cytometry. Apoptosis was measured by FACS (cells were labeled with annexin-V-FITC and PI). Apoptosis was increased after coincubation of the cells with R-EXOs from AML blast patients compared to EXOs from HDs **(C)**  $p < 0.003$ , **(D)**  $p < 0.001$ , and **(E)**  $p < 0.03$ . **F** Representative FACS histogram of the percentage of GFP transferred from R-EXOs to T cells. The data are the mean  $\pm$  SEM from experiments with eight AML samples. Representative data from five independent experiments are shown. All values are shown as the mean  $\pm$  SEM. \* $p < 0.05$ ; \*\* $p < 0.01$  and \*\*\* $p < 0.001$

both major CD4+ and CD8+ T lymphocyte subtypes, significantly increased after incubation with R-EXOs (10 µg/ml of the EXOs); the control EXOs did not result in an increase in apoptosis (Fig. 1C, D and E). Finally, to confirm material transfer from released R-EXOs to T cells, we have used a strategy previously described and validated by E. Geurickx et al. on the use of trackable recombinant EVs (rEVs) [20]. GFP was overexpressed in EXOs by transducing the K562, KG1 and HL60 blast cell lines with a lentiviral vector expressing GFP. CD3 T cells were coincubated with the generated EXOs-GFP for 3 days and analyzed by FACS. The results showed an increase of 35% in the GFP signal of T cells compared to that of the control T cells (Fig. 1F). These results indicate that released factors from EXOs can be transferred to T cells.

### miR-24-3p in AML blast R-EXOs is a key player in T-cell apoptosis

According to previously published data on the circulating miRNA profile in AML patients and based on its biological relevance in AML, we selected EXO-miR-24-3p as a key candidate to further study and characterize its potential effects on AML T cells. As miRNAs have been reported to be transferred from tumor cells to IME recipient cells, we first tested whether miR-24-3p was present in R-EXOs. Our first analysis using qPCR showed a significantly increased level of miR-24-3p in R-EXOs (Fig. 2A) ( $p < 0.007$ ). In addition, we investigated whether miR-24-3p could be transferred from EXOs to recipient T cells. Following coincubation with 8 R-EXO samples, we found a significantly increased level of miR-24-3p in recipient T cells compared to that of the

### MiR-24-3p expression in R-EXOs of AML patients




**Fig. 2** The expression level of miR-24-3p in CD3 T cells and EXOs in AML patients. Relative miR-24-3p expression assessed by qRT-PCR (A) in EXOs isolated from peripheral blood AML blast culture supernatant ( $n = 10$ ) compared to that of HDs ( $n = 3$ ), (B) in HD-isolated CD3 T cells after incubation with AML EXOs ( $n = 8$ ) or HD EXOs ( $n = 5$ ), (C) and in CD3 T cells freshly isolated from AML patient peripheral blood ( $n = 16$ ) compared to that of 10 HDs. D, E HD CD3 T cells were cultured in the presence of miR-24-3p-enriched EXOs (Exo-miR-24-3p) or anti-miR-24-3p-enriched EXOs (Exo-anti-miR-24-3p) for 5 days; CD3 T cells cultured in the medium were used as controls. The degree of apoptosis was measured by FACS (cells were labeled with annexin-V-FITC and PI). Enriched EXOs (E-EXOs) were obtained from the culture supernatant of the K562 blast cell line overexpressing miR-24-3p after lentivirus-24-3p vector (miR-24-3p-EXO) transduction or anti-miR-24-3p-EXO in which anti-miR-24-3p was expressed by transducing K562 cells with a lenti-anti-miR-24-3p vector. D Treatment of T cells with E-EXOs increased miR-24-3p expression in T cells. E miR-24-3p-EXO treatment significantly increased the apoptosis level of T cells ( $***, p < 0.001$ ), while anti-miR-24-3p-EXO significantly decreased apoptosis compared to the control ( $*** p < 0.002$ ). Bar graphs represent the mean  $\pm$  SEM  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$

exosome control-treated cells ( $p < 0.003$ ) (Fig. 2B). We also quantified miR-24-3p expression in 16 freshly isolated AML patient T cells. Importantly, we found that the expression of miR-24-3p was significantly increased in AML patient T cells compared to HD T cells (Fig. 2C). To further confirm that exosomal miR-24-3p is functional and is a major player in the AML T-cell alteration that contributes to apoptosis, we generated miR-24-3p-enriched EXOs from the culture supernatant of the K562 and HL60 blast cell lines overexpressing miR-24-3p after lentivirus-24-3p vector (miR-24-3p-EXO) transduction. Conversely, we also generated anti-miR-24-3p-enriched EXOs (anti-miR-24-3p-EXOs) in which anti-miR-24-3p was expressed by transducing cell lines with a lenti-antagomiR-24-3p vector. We found that miR-24-3p overexpression in cell lines significantly increased the level of miR-24-3p in the secreted EXOs (Fig. 2D), which in turn significantly increased the apoptosis of T cells treated with miR-24-3p-EXOs compared with EXOs-control ( $p < 0.001$ ), while anti-miR-24-3p-EXOs significantly

decreased T-cell apoptosis ( $p < 0.002$ ) (Fig. 2E). Taken together, these results suggest that miR-24-3p present in R-EXOs is a key player in induction of T-cell apoptosis.

**Impact of miR-24-3p on T-cell function and mechanism of action**

To fully explore the effect of exosomal miR-24-3p on T cells, we overexpressed miR-24-3p in T cells by transducing HD T cells with a lenti-miR vector construct expressing miR-24-3p or a control vector. Both vectors expressed GFP, which was used to evaluate the transduction efficiency (Fig. 3A). qRT-PCR analysis of miR-24-3p expression after transduction of T cells revealed a significant difference in its expression compared to that of the controls (Fig. 3A). FACS analysis demonstrated that miR-24-3p significantly increased apoptosis in CD3 T cells ( $p < 0.0002$ ) and both CD4+ ( $p < 0.0001$ ) and CD8+ T-cell ( $p < 0.002$ ) subtypes (Fig. 3B). In contrast, as shown in Fig. 3C, the blockade of miR-24-3p



**Fig. 3** Primary CD3, CD4 and CD8 T lymphocytes purified from HDs' peripheral blood were transduced by the LV-miR-24-3p construct containing GFP. **A** miR-24-3p expression levels after transduction were determined by qRT-PCR in RNA extracted from the lenti-miR-ctrl (black bar) and lenti-miR-24-3p groups ( $n = 5$ ). CD3 T cells were transduced with an efficiency of 93–94%, as shown by flow cytometry. Lentiviral transduction increased miR-24-3p expression in CD3 T cells. **B** Apoptosis was measured by FACS (cells were labeled with annexin-V-FITC and PI). The overexpression of miR-24-3p induced apoptosis in T cells (CD3, CD4 and CD8) compared to the negative control [CD3 (\*\* $n = 5$ ,  $p < 0.0002$ ), CD4 ( $n = 5$  \*\*\* $p < 0.0001$ ), CD8 ( $n = 5$  \*\* $p < 0.002$ )]. **C** Primary CD3 T lymphocytes purified from peripheral blood from AML patients were transduced with the LV-anti-miR-24-3p construct containing GFP, and the expression of GFP after transduction was measured by FACS (94%) (mean  $\pm$  SEM,  $n = 5$ ). The inhibition of miR-24-3p expression by anti-miR-24-3p decreased cell apoptosis (cells were labeled with annexin-V-FITC and PI) compared to that of the scrambled anti-miR control group. All values are shown as the mean  $\pm$  SEM,  $n = 5$ . \* $p < 0.05$ ; \*\* $p < 0.001$ , \* $p < 0.02$ . **D** RT-qPCR analysis of the immunosuppressive, antiapoptotic and proapoptotic genes. **E** Western blot analysis of the antiapoptotic proteins Bcl-2 and Xiap and the proapoptotic proteins caspase-9 and caspase-3 after transduction of CD3 T cells from HDs by the LV-miR-24-3p construct containing GFP or the lenti-CTRL-GFP construct and CD3 T cells from AML patients




by antagomiR-24-3p significantly decreased CD3 T-cell apoptosis in AML patients compared to the controls ( $p < 0.01$ ). Our T-cell transduction results confirmed that miR-24-3p expression is involved in regulation of T-cell apoptosis in AML patient T cells.

Consistent with the role of miR-24-3p in T-cell apoptosis, we found that miR-24-3p overexpression lowered the expression level of antiapoptotic proteins such as Bcl-2 and Xiap (Fig. 3D). Furthermore, the role of miR-24-3p in reducing the expression of the antiapoptotic proteins XIAP and Bcl2 was confirmed by Western blotting (Fig. 3E). We also showed its positive impact on the levels of cleaved caspase-9 and caspase-3 compared to those of the scrambled miRNA control as well as their slight protection from activation after miR-24-3p silencing by antagomiR (Fig. 3E). Taken together, these results indicate that miR-24-3p activates intrinsic apoptosis and promotes a suppressive protumoral profile in T cells.

**miR-24-3p directly targets and inhibits DENN/MADD expression in T cells**

To further explore the molecules responsible for miR-24-3p-mediated T-cell apoptosis, we searched for the downstream target genes of miR-24-3p using miRNA bioinformatics software (TargetScan, PicTar and miRDB). These analyses revealed hundreds of potential mRNA targets for miR-24-3p, but we first focused on genes that have been reported to play crucial roles in apoptosis signaling pathways. Among these putative target genes, DENN/MADD was chosen for further experimental confirmation. To subsequently investigate whether miR-24-3p could regulate the DENN/MADD gene, we cloned fragments containing the predicted target sites in the 3'UTR of DENN/MADD or mutated binding sites into a vector with a luciferase reporter gene. The luciferase assay results showed that the relative luciferase Renilla activity was significantly reduced when miR-24-3p



**Fig. 4** The DENN/MADD gene is a direct downstream target of miR-24-3p: validation by luciferase assays and Western blot: **(A)** a human DENN/MADD 3'-UTR fragment containing a WT or MT miR-24-3p binding sequence was cloned downstream of the luciferase reporter gene. The plasmids were transfected into K562 and HL62 cells with or without miR-24-3p mimics. Renilla luciferase plasmids were cotransfected for normalization. A pGL3-control vector was cotransfected as a positive control. Analysis of luciferase activity: The data from the reporter assays are presented as the mean  $\pm$  SEM from three independent experiments performed in triplicate (K562\*\*\* $p < 0.0005$ ) (HL62, \*\*\* $p < 0.0006$ ). **(B)** Western blot and qPCR analysis of DENN/MADD expression after HD CD3 T-cell transduction by LV-miR-24-3p or lenti-CTRL and AML CD3 T-cell transduction by the antagomiR-miR-24-3p-GFP or lenti-CTRL construct showed that miR-24-3p reduces both the mRNA and protein levels of DENN/MADD ( $n = 3$ ). **(C)** qPCR quantification of relative DENN/MADD expression in CD3 T cells from AML patients ( $n = 13$ ) compared to ( $n = 5$ ) HDs. (\*\* $p < 0.001$ ) **(D)** **(E)** Correlation between DENN/MADD mRNA expression in T cells and miR-24-3p in EXOs and in T cells, quantified by qPCR. DENN/MADD expression in T cells is negatively correlated with **(D)** serum exosomal miR-24-3p level ( $R = -0.2460, p < 0.007$ ) and **(E)** miR-24-3p in T cells ( $R = -0.3, p < 0.007$ ). The statistical analysis was performed with Spearman's correlation and linear regression


mimics were cotransfected with the luciferase reporters compared to the control, while there was no inhibition of luciferase activity following transfection with miR-24-3p in the mutant reporter ( $p < 0.0006$ ) (Fig. 4A). Next, Western blot analysis showed that DENN/MADD was notably decreased by the overexpression of miR-24-3p, while its expression level increased when miR-24-3p inhibitors were used (Fig. 4B). Moreover, we found that DENN/MADD was downregulated in the T cells of leukemia patients compared to HDs ( $p < 0.006$ ) (Fig. 4C) and was inversely correlated with increased exosomal miR-24-3p and miR-24-3p levels in the CD3 T cells of leukemia patients (Fig. 4D and E). Taken together, these results indicate that DENN/MADD is a major target of miR-24-3p.

To test whether induced T-cell apoptosis required DENN/MADD inhibition, we targeted DENN/MADD by specific short interfering RNAs (siRNAs). The results showed that lenti-siRNA-DENN/MADD-transduced T cells had an increased apoptosis rate compared with lenti-siRNA-control-transduced T cells ( $p < 0.0003$ )

(Fig. 5A). Furthermore, T-cell overexpression of DENN/MADD substantially decreased apoptosis following R-EXO treatment, as did the miR-24-3p inhibitor ( $p < 0.001$ ). Hence, T-cell survival was rescued by DENN/MADD overexpression following R-EXO treatment (Fig. 5B). Taken together, these data indicated that T-cell apoptosis induced by miR-24-3p upregulation may act through the regulation of DENN/MADD.

**miR-24-3p inhibits the NF-κB and JAK/STAT signaling pathways in human T cells**

We next tested whether miR-24-3p might affect downstream signaling pathways in T cells. NF-κB, JAK/STAT and ERK were reported as important regulators of both T-cell function and cytokine production. However, the cell surface receptor TNFR1 can promote cell survival via the activation of NF-κB signaling pathways. Consistent with this finding, after transfection of T cells with miR-24-3p mimic or inhibitor, Western blot analysis revealed that miR-24-3p inhibited p-NF-κB and the expression of TNFR1 receptors. p-NF-κB and



**Fig. 5** miR-24-3p inhibited the JAK/STAT and NF-κB signaling pathways: **A** DENN/MADD knockdown by lenti-siRNA-DENN/MADD transfection significantly increased HD T-cell apoptosis levels compared to the control ( $n = 5$   $**p < 0.003$ ). Lenti-siRNA was included as a control. **B** R-EXO-induced apoptosis is rescued by DENN/MADD overexpression in HD CD3 T cells. **C** Western blot analysis of the NF-κB and JAK/STAT signaling pathways. The overexpression of miR-24-3p by T-cell transfection with miR-24-3p mimic decreased the expression levels of NF-κB and TNFR1, while its inhibition increased their expression. miR-24-3p decreases the expression of p-ERK protein. **D** The overexpression of miR-24-3p after transfection with the miR-24-3p mimic decreased the levels of p-JAK1, p-STAT1, and p-STAT3, which were recovered by the inhibition of miR-24-3p by the miR-24-3p inhibitor mimic. The β-actin gene was included as a control. **E** The levels of p-NFκB and p-ERK were lower in lenti-siRNA-DENN/MADD-transduced T-cells than in lenti-siRNA control cells. **F** The level of the p-ERK protein was lower in lenti-siRNA-DENN/MADD-transduced T cells than in lenti-siRNA control-transfected T cells. For (C, D, E, and F), the figure shows representative Western blot data from three independent experiments. **A** Bar graphs represent the mean ± SEM  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$




the expression of TNFR1 receptors were recovered after transfection with either inhibitor (Fig. 5C). Similarly, the transfection of miR-24-3p mimics decreased the T-cell phosphorylated levels of JAK1, STAT1, and STAT3 compared to those of the negative control, while they were clearly increased after transfection with either inhibitor (Fig. 5D). In addition, miR-24-3p decreased the level of p-ERK, which was significantly increased by the miR-24-3p inhibitor (Fig. 5D). DENN/MADD is an adaptor protein that exerts an antiapoptotic role by binding to TNFR1, leading to the activation of cell survival via the activation of the NF-κB signaling network. As we showed that miR-24-3p silenced DENN/MADD in T cells, we investigated whether DENN/MADD could shape p-NF-κB signaling pathways. However, after targeting of DENN/MADD by lenti-siRNA (lenti-siRNA-DENN/MADD), Western blot analysis revealed a significant reduction in the phosphorylation level of NF-κB and the expression of TNFR1 (Fig. 5E). Furthermore, we found that p-ERK

was reduced in the lenti-siRNA-DENN/MADD-transduced T cells compared with the lenti-siRNA- control-transduced T cells (Fig. 5F). These results demonstrated that miR-24-3p affects the function of T cells by down-regulating DENN/MADD and consequently altering the NF-κB signaling network, which indirectly alters the p-JAK/STAT and p-ERK signaling pathways. These data showed that miR-24-3p, by regulating its putative direct target, can alter downstream signaling pathways of its target.

**miR-24-3p promotes the development of human tregs**

Increases in Treg cells in the bone marrow and blood of AML patients have been reported in several studies and have been shown to hinder the graft-versus-tumor effect in AML [2, 21–23]. To investigate whether exosomal miR-24-3p stimulates the development of human D4+CD25+CD127low regulatory T cells (Tregs), we treated Treg cells isolated from healthy donor PBMCs with miR-24-3p-EXOs or anti-miR-24-3p-EXOs. We found that

**The miR-24-3p reduced Treg CD4-CD25 (FOXP3+) apoptosis, stimulate proliferation**



**Fig. 6** miR-24-3p promoted the development of Treg cells in AML. **A** Isolated Treg cells were cultured in the presence of Exo-miR-24-3p or Exo-anti-miR-24-3p for 5 days; Treg cells cultured in the medium were used as controls. The degree of apoptosis was measured by FACS (cells were labeled with annexin-V-FITC and PI). miR-24-3p-EXOs significantly decreased the apoptosis of Tregs compared with anti-miR-24-3p-EXOs ( $p < 0.0001$ ). **B** CD4+CD25+Foxp3+ Tregs purified from HDs' peripheral blood were transduced by the LV-miR-24-3p construct. Apoptosis was measured by FACS, and the overexpression of miR-24-3p decreased Treg apoptosis compared to the negative control ( $n = 5$ ,  $*** p < 0.0002$ ). **C** Western blot analysis of the expression level of phosphorylated proteins of the JAK/STAT signaling pathways: p-JAK3 and p-STAT5. **D** p-NF-κB and p-ERK in Treg cells after overexpression or inhibition of the miR-24-3p mimic. The overexpression of miR-24-3p by transfection of T cells with miR-24-3p mimic decreased the expression levels of p-NF-κB and p-ERK protein. The β-actin gene was included as a control. Representative data from three independent experiments are shown

miR-24-3p-EXOs significantly decreased the apoptosis of Tregs compared to that of control Tregs, while anti-miR-24-3p-EXO treatment significantly increased apoptosis ( $p < 0.0001$ ) (Fig. 6A). To study the potential effect of exosomal miR-24-3p on Treg induction, we overexpressed miR-24-3p by transduction in Tregs, which decreased the apoptosis rate compared with that of Tregs transduced with the lentimiR-control ( $p < 0.0002$ ) (Fig. 6B). In addition, the overexpression of miR-24-3p by transfecting miR-24-3p mimic or inhibitor into Treg cells increased the phosphorylation of JAK3 and STAT5, which was significantly reduced after miR-24-3p inhibitor transfection (Fig. 6C). Moreover, the miR-24-3p mimic activated p-NF- $\kappa$ B and increased the expression of TNFR1. p-ERK was also increased after miR-24-3p transfection and decreased after inhibition (Fig. 6D). Taken together, these results indicated that miR-24-3p promotes human Treg generation and its immunosuppressive profile.

## Discussion

To enhance their survival and development, cancer cells impair the antitumor immune response by inhibiting effector T cells and promoting suppressor and regulatory T cells [2]. The capacity of cancer cells to induce T-cell apoptosis has been shown in several studies [4, 20]. In AML, T-cell dysfunction and induced T-cell apoptosis are also known to support leukemic progression [5]. Numerous studies have highlighted the key involvement of extracellular vesicles, including EXOs, released from cancer cells to actively promote disease by modulating the IME [24]. As several miRNAs have been demonstrated to regulate the immune response in cancer [25–28], our results provide a novel mechanism for understanding the role of exosomal miRNAs in the crosstalk between cancer cells and the surrounding IME, which coordinates T-cell impairment.

Importantly, the death of effector T cells induced by cancer has been reported to be responsible for tumor escape, suggesting its involvement in facilitating cancer evasion from the host immune system [29]. Our preliminary observations showed that R-EXOs induced CD3 T-cell apoptosis, including that of CD4+ and CD8+ T cells. This finding suggests that the functions of R-EXOs derived from AML blasts could be a pivotal mechanism associated with T-cell dysfunction and indicates that they could be involved in leukemia immune evasion. T-cell apoptosis induced by leukemic R-EXOs could indeed provide an alternative mechanism for the loss of the T-cell antitumor ability to initiate immunosuppression. These immunosuppressive effects of EXOs could be associated with the accumulation of other immune-suppressor factors. However, many molecular components found within several released EXOs can generate a similar effect

[30–32]; consequently, they could be responsible for the observed immune T-cell phenotype. Currently, many studies have indicated the role of oncomiRs in the suppression of the antitumor response to promote cancer progression. Given that some oncomiRs are reported to be involved in the suppression of the antitumor response in cancers [33–35], we investigated whether R-EXO-miRNAs were involved in T-cell impairment in AML.

The circulating miRNA profile in AML revealed a panel of highly expressed miRNAs. Based on differential expression analysis, we identified miR-24-3p as one of the top miRNAs significantly upregulated in AML and a key candidate to further study and characterize its potential effects on AML. miR-24-3p has been reported to be aberrantly expressed in many cancer types [20–22, 36], and its upregulation in AML has been associated with poor prognosis and risk of relapse [37]. However, the specific role of miR-24-3p and the molecular mechanisms underlying its role in AML promotion have yet to be elucidated. When we examined the possible presence of miR-24-3p in R-EXOs from AML patient blasts, we found that miR-24-3p was highly enriched in R-EXOs. These data were corroborated by two recent publications showing that miR-24-3p is overexpressed in R-EXOs [38], and it was highly expressed in the plasma of bone marrow from AML patients at diagnosis with normalization of its expression in remission [39]. Moreover, we found a significant increase in miR-24-3p levels in T cells following treatment with R-EXOs as well as in T cells freshly isolated from AML patients. This finding suggested that R-EXOs mediated their effects through the delivery of miR-24-3p to T cells, indicating that miR-24-3p might be a major player in T-cell impairment mediated by R-EXOs. In fact, miR-24-3p is not the only component found in EXOs; the possibility that other suppressive factors may contribute to the same phenotype cannot be excluded. However, these results were confirmed by the ex vivo-generated miR-24-3p-enriched-EXO effect on T cells, showing a significant increase in apoptosis after miR-24-3p-EXO treatment, as well as a significant increase in the miR-24-3p level found in T cells, demonstrating clearly that R-EXOs can deliver individual miRNAs to T cells and shape their function in an efficiency-relevant manner. In contrast, anti-miR-24-3p administration restored the survival capacity of T cells, revealing that exosomal miR-24-3p was indeed specifically contributing to apoptosis.

miRNAs are important regulators of major stages in cancer development, from tumor escape to immune surveillance to tumor microenvironment reprogramming. Notably, the ability of some oncogenic miRNAs to regulate the immune response toward immune escape in cancer has been widely described. Furthermore, we showed


that exosomal miR-24-3p exhibited an inhibitory effect on T-cell survival by inducing apoptosis. The ability of miR-24-3p to regulate apoptosis occurs through silencing different signaling targets related to apoptosis, such as the antiapoptotic proteins DENN/MADD, BCL2 and XIAP, and increased expression of proapoptotic proteins, such as caspase-9 and caspase-3. Consistent with our findings, miR-24-3p has been described to impede T cells in non-small cell lung cancer (NSCLC) by targeting FGF11, a growth factor involved in the proliferation of T cells [20].

Furthermore, for the first time, using luciferase technology, we demonstrated that DENN/MADD is a direct downstream target of miR-24-3p. DENN/MADD has been reported as a death domain (DD)-containing protein that interacts with TNFR1 [40, 41]; DENN/MADD competes with the binding of TRADD and skews the signaling pathway toward cell survival [42, 43]. Moreover, DENN/MADD was shown to be necessary for T-cell survival because its blockade by specific siRNAs contributes to T-cell apoptosis, and its overexpression could restore the inhibitory effect of miR-24-3p on T-cell survival. However, miR-24-3p overexpression altered NF-κB signaling networks, which enhanced the susceptibility to apoptosis. These results suggest that apoptosis induced by miR-24-3p upregulation may act through

the regulation of DENN/MADD and may be one of the mechanisms responsible for T-cell apoptosis in AML. Nevertheless, we could not exclude the possibility that other miRNAs may function synergistically with miR-24-3p to hinder T cells in AML. The regulatory role of miRNAs is particularly complex because miRNAs can alter the functions of multiple other targets at the same time. The exact molecules and the global mechanism that cause AML T-cell impairment may require more investigation, but mechanistic analysis has shown that miR-24-3p acts as an endogenous siRNA for DENN/MADD; moreover, miR-24-3p overexpression by itself affected T-cell viability through the inhibition of the NF-κB, JAK/STAT and ERK signaling pathways, which were reported as an important regulator of both T-cell function and cytokine production. Overall, the association of circulating R-EXO-miR-24-3p and the phenotype of T cells in AML confirms the critical role of miR-24-3p in cancer malignancies. This ability of miRNAs to target multiple signaling networks involved in regulating various aspects of T-cell biology makes them promising effective T-cell therapies for cancer treatment.

Treg infiltration in tumors is linked to poor relapse-free survival of cancer patients [44, 45]. R-EXOs can increase immunosuppressive cells such as Tregs, myeloid-derived suppressor cells (MDSCs) and TGF-β-secreting cells at

Summary of exosomal miR-24-3p action on T cells in AML



**Fig. 7** Mechanistic model of the role of miR-24-3p: miR-24-3p regulates T-cell apoptosis induction. **Signal I:** When TNF binds to TNFR1, it leads to the activation of cell survival via the activation of the NF-κB signaling network and JAK/STAT proteins and hence apoptotic resistance. **Signal II:** Overexpression of miR-24-3p through derived EXOs silences DENN/MADD expression, which induces the apoptosis signaling network through the deregulation of NF-κB and JAK/STAT and ERK phosphorylation. miR-24-3p increases the expression of caspase 9 and 3, inducing apoptosis. Finally, miR-24-3p impedes T-cell function through the Jak/STAT and NF-κB signaling networks. miR-24-3p is therefore a key player in AML escape from T-cell-mediated cytotoxicity and largely contributes to blast survival

tumor sites while directly inhibiting effector antitumoral T cells [29, 46]. Moreover, in cancer, some miRNAs with oncogenic effects contribute to the expansion and accumulation of Tregs and thereby promote cancer progression [46–48]. Research on the impact of miR-24-3p on Tregs is limited. Recently, miR-24-3p was shown to promote the expansion of Tregs through the stimulation of STAT5 and inhibition of STAT1 in NSCLC [20]. Our data indicated that miR-24-3p promotes the development of Tregs by reducing apoptosis, which is consistent with previous studies showing that Tregs increased at diagnosis in AML [2, 21–23]. Notably, miR-24-3p activates NF- $\kappa$ B and preferentially activates JAK3/STAT5 signaling pathways. These results are consistent with a study showing that the IL2/JAK3/STAT-5-axis regulates Foxp3 in Tregs [49]. Finally, the concrete molecular mechanisms involved in miR-24-3p-mediated Treg development are still only partly understood.

In summary, the mechanistic model by which R-EXO-miR-24-3p induced T-cell apoptosis is illustrated in Fig. 7. The results of our study show that R-EXO-miR-24-3p leads to T-cell apoptosis by targeting DENN/MADD and consequently inhibiting the activity of NF- $\kappa$ B, JAK/STAT and ERK in the MAPK signaling pathways and promoting Tregs, contributing to cancer tolerance in the tumor microenvironment (TME). The recent clinical performance of immune therapies in cancer has led researchers to focus principally on the role of efficient T cells targeting cancer cells. While immunotherapies are successful in promoting the ex vivo T-cell immune responses, in vivo T cells are subject to various suppressor processes that can hinder their functions. Our results suggest that miRNAs represent an important mechanism mediating cancer tolerance. The development of therapeutic strategies based on blocking defined miRNAs or protecting their targets offers a rational approach that is interesting to consider. While more work is needed, targeting miR-24-3p in AML appears to represent a line of thought for new leukemia treatment strategies.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12964-023-01259-1>.

#### Additional file 1.

### Acknowledgements

We thank the “Association Jules Bordet” for its support.

### Authors' contributions

Otmani Khalid: Conceptualization, Methodology, Investigations, Validation and Formal analysis, Writing the draft of the paper and paper correction and revision. Redouane Rouas: Conceptualization, Formal analysis, Validation, Supervision, Paper correction and revision. Laurence Lagneaux: exosomes isolations: Methodology, Supervision, Formal analysis. Mohammad Krayem: western blot:

Methodology, Supervision, Ressources. Hugues Duveiller: Flow cytometry: Conceptualization, Formal analysis, Supervision. Mimoune Berehab: Methodology, Formal analysis. Philippe lewalle: Conceptualization, Formal analysis, Validation, Supervision, paper correction and revision, Funding acquirement, Project administration, Ressources.

### Funding

This research was supported by a funding from “Association Jules Bordet and a grant from Foundation Lambeau-Marteaux.

### Availability of data and materials

The data and materials are available upon the request.

### Declarations

#### Ethics approval and consent to participate

This work was approved by the Ethics committee of the Institut Jules Bordet and all participants gave their consent to participate.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare no competing interests.

#### Author details

<sup>1</sup>Experimental Hematology Laboratory, Hematology Department, Hôpital Universitaire de Bruxelles, (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, 90 Meylemeersch Street, 1070 Brussels, Belgium. <sup>2</sup>Laboratoire de Thérapie Cellulaire Clinique (LTCC), Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. <sup>3</sup>Laboratory of Clinical and Experimental Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. <sup>4</sup>Flow Cytometry Facility, Hôpital Universitaire de Bruxelles (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Received: 8 June 2023 Accepted: 7 August 2023

Published online: 21 September 2023

### References

- Gbolahan OB, et al. Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment. *Int J Mol Sci.* 2017;18(8):1–19. <https://doi.org/10.3390/ijms18081660>.
- Lamble AJ, Lind EF. Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity. *Front Oncol.* 2018;8:1–13. <https://doi.org/10.3389/fonc.2018.00213>.
- Tian T, et al. The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations. *PLoS ONE.* 2015;10(7):1–19. <https://doi.org/10.1371/journal.pone.0131761>.
- Le Dieu R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. *Blood.* 2009;114(18):3909–16. <https://doi.org/10.1182/blood-2009-02-206946>.
- Knaus HA, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. *JCI insight.* 2018;3(21):e120974. <https://doi.org/10.1172/jci.insight.120974>.
- K. Otmani, R. Rouas, and P. Lewalle, “OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications,” *Front. Immunol.*, vol. 13, no. September, pp. 1–17, 2022, doi: <https://doi.org/10.3389/fimmu.2022.913951>.
- Bartel DP, Lee R, Feinbaum R. MicroRNAs : Genomics , Biogenesis , Mechanism , and Function *Genomics.* The miRNA Genes. 2004;116:281–97.
- Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell.* 2004;116(2):281–97. [https://doi.org/10.1016/S0092-8674\(04\)00045-5](https://doi.org/10.1016/S0092-8674(04)00045-5).
- O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. *Nat Rev Immunol.* 2010;10(2):111–22. <https://doi.org/10.1038/nri2708>.



10. Guo W, Li Y, Pang W, Shen H. Exosomes: a potential therapeutic tool targeting communications between tumor cells and macrophages. *Mol Ther*. 2020;28(9):1953–64. <https://doi.org/10.1016/j.yjthe.2020.06.003>.
11. Qian M, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF- $\kappa$ B pathways. *Oncogene*. 2020;39(2):428–42. <https://doi.org/10.1038/s41388-019-0996-y>.
12. Fanini F, Fabbri M. Cancer-derived exosomal microRNAs shape the immune system within the tumor microenvironment: State of the art. *Semin Cell Dev Biol*. 2017;67:23–8. <https://doi.org/10.1016/j.semcdb.2016.12.004>.
13. Graner MW, Schnell S, Olin MR. Tumor-derived exosomes, microRNAs, and cancer immune suppression. *Semin Immunopathol*. 2018;40(5):505–15. <https://doi.org/10.1007/s00281-018-0689-6>.
14. Tadokoro H, Umezumi T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. *J Biol Chem*. 2013;288(48):34343–51. <https://doi.org/10.1074/jbc.M113.480822>.
15. Zhao G, et al. Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. *Tumor Biol*. 2015;36(5):3693–701. <https://doi.org/10.1007/s13277-014-3008-4>.
16. Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS, Chang KW. miR-24 up-regulation in oral carcinoma: Positive association from clinical and in vitro analysis. *Oral Oncol*. 2010;46(3):204–8. <https://doi.org/10.1016/j.oraloncology.2009.12.005>.
17. Naito Y, et al. Characteristic MIR-24 expression in gastric cancers among atomic bomb survivors. *Pathobiology*. 2015;82(2):68–75. <https://doi.org/10.1159/000398809>.
18. Chen X, Xiong W, Li H. Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia. *Oncol Lett*. 2016;12(6):4937–48. <https://doi.org/10.3892/ol.2016.5308>.
19. Koga K, et al. Purification, characterization and biological significance of tumor-derived exosomes. *Anticancer Res*. 2005;25(6 A):3703–7.
20. Ye SB, et al. Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. *J Pathol*. 2016;240(3):329–40. <https://doi.org/10.1002/path.4781>.
21. Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function - Implications for the adoptive immunotherapy of leukaemia. *Clin Exp Immunol*. 2001;126(3):403–11. <https://doi.org/10.1046/j.1365-2249.2001.01692.x>.
22. Zhou Q, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. *Blood*. 2009;114(18):3793–802. <https://doi.org/10.1182/blood-2009-03-208181>.
23. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud Ø. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating T<sub>H</sub>1, T<sub>H</sub>17 and T<sub>REG</sub> cells. *BMC Immunol*. 2010;11:1–2. <https://doi.org/10.1186/1471-2172-11-38>.
24. Liu H, et al. Intestinal CD14<sup>+</sup> macrophages protect CD4<sup>+</sup> T cells from activation-induced cell death via exosomal membrane TNF in Crohn's disease. *J Crohn's Colitis*. 2020;14(11):1619–31. <https://doi.org/10.1093/ecco-jcc/jjaa083>.
25. R. Ueda et al., "resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1," *Direct*, pp. 1–6, 2009.
26. Gao F, et al. MiR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. *Biochem Biophys Res Commun*. 2013;431(3):610–6. <https://doi.org/10.1016/j.bbrc.2012.12.097>.
27. Whiteside TL. The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. *Futur Oncol*. 2017;13(28):2583–92. <https://doi.org/10.2217/fon-2017-0343>.
28. Zhang LL, Zhang LF, Shi YB. miR-24 inhibited the killing effect of natural killer cells to colorectal cancer cells by downregulating Paxillin. *Biomed Pharmacother*. 2018;101:257–63. <https://doi.org/10.1016/j.biopha.2018.02.024>.
29. Liu J, et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. *Hepatology*. 2019;70(1):241–58. <https://doi.org/10.1002/hep.30607>.
30. Li B, Cao Y, Sun M, Feng H. Expression, regulation, and function of exosome-derived miRNAs in cancer progression and therapy. *FASEB J*. 2021;35(10):1–12. <https://doi.org/10.1096/fj.202100294RR>.
31. Groza M, et al. Recent advancements in the study of breast cancer exosomes as mediators of intratumoral communication. *J Cell Physiol*. 2020;235(2):691–705. <https://doi.org/10.1002/jcp.29096>.
32. Parayath NN, Padmakumar S, Amiji MM. Extracellular vesicle-mediated nucleic acid transfer and reprogramming in the tumor microenvironment. *Cancer Lett*. 2020;482(March):33–43. <https://doi.org/10.1016/j.canlet.2020.04.009>.
33. Veziroglu EM, Mias GI. Characterizing extracellular vesicles and their diverse RNA contents. *Front Genet*. 2020;11(July):1–30. <https://doi.org/10.3389/fgene.2020.00700>.
34. Wang X, et al. The advancing roles of exosomes in breast cancer. *Front Cell Dev Biol*. 2021;9(November):1–16. <https://doi.org/10.3389/fcell.2021.731062>.
35. Bejarano L, Jordão MJ, Joyce JA. Therapeutic targeting of the tumor microenvironment. *Cancer Discov*. 2021;11(4):933–59. <https://doi.org/10.1158/2159-8290.CD-20-1808>.
36. Liu Z, Jiang L, Zhang G, Li S, Jiang X. MiR-24 promotes migration and invasion of non-small cell lung cancer by targeting ZNF367. *J BUON*. 2018;23(5):1413–9.
37. Organista-Nava J, et al. High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia. *Oncol Rep*. 2015;33(4):1639–49. <https://doi.org/10.3892/or.2015.3787>.
38. Moussa Agha D, et al. Impact of bone marrow miR-21 expression on acute myeloid leukemia T lymphocyte fragility and dysfunction. *Cells*. 2020;9(9):1–18. <https://doi.org/10.3390/cells9092053>.
39. Agha DM, et al. Identification of acute myeloid leukemia bone marrow circulating microRNAs. *Int J Mol Sci*. 2020;21(19):1–31. <https://doi.org/10.3390/ijms21197065>.
40. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF- $\kappa$ B pathway. *FEBS J*. 2011;278(6):862–76. <https://doi.org/10.1111/j.1742-4658.2011.08015.x>.
41. Schievella AR, Chen JH, Graham JR, Lin LL. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. *J Biol Chem*. 1997;272(18):12069–75. <https://doi.org/10.1074/jbc.272.18.12069>.
42. Del Villar K, Miller CA. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. *Proc Natl Acad Sci U S A*. 2004;101(12):4210–5. <https://doi.org/10.1073/pnas.0307349101>.
43. Ghorbani S, Talebi F, Ghasemi S, Abad AJ, Voigani M, Noorbakhsh F. MiR-181 interacts with signaling adaptor molecule DENN/MADD and enhances TNF-induced cell death. *PLoS ONE*. 2017;12(3):1–14. <https://doi.org/10.1371/journal.pone.0174368>.
44. Wang X, et al. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3<sup>+</sup> Treg cells in pancreatic ductal adenocarcinoma. *Oncogene*. 2017;36(21):3048–58. <https://doi.org/10.1038/ncr.2016.458>.
45. Chen X, Du Y, Lin XQ, Qian Y, Zhou T, Huang ZM. CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells in tumor immunity. *Int Immunopharmacol*. 2016;34:244–9. <https://doi.org/10.1016/j.intimp.2016.03.009>.
46. Ning T, et al. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. *Mol Ther*. 2021;29(9):2723–36. <https://doi.org/10.1016/j.yjthe.2021.04.028>.
47. Hu Y, et al. MiR-21 controls in situ expansion of CCR6<sup>+</sup> regulatory T cells through PTEN/AKT pathway in breast cancer. *Immunol Cell Biol*. 2015;93(8):753–64. <https://doi.org/10.1038/icb.2015.37>.
48. Lu LF, et al. Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 Protein. *Immunity*. 2009;30(1):80–91. <https://doi.org/10.1016/j.immuni.2008.11.010>.
49. Goldstein JD, et al. Inhibition of the JAK/STAT signaling pathway in regulatory T cells reveals a very dynamic regulation of foxp3 expression. *PLoS ONE*. 2016;11(4):1–16. <https://doi.org/10.1371/journal.pone.0153682>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.